# Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

> **NCT03154619** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SerenaGroup, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Venous Leg Ulcer

## Interventions

- **DRUG:** 0.1% TR 987
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT03154619
- **Lead sponsor:** SerenaGroup, Inc.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11
- **Primary completion:** 2019-04-04
- **Final completion:** 2021-04-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154619, "Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03154619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*